Literature DB >> 24213573

Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).

I-C Wang1, V Ustiyan2, Y Zhang2, Y Cai2, T V Kalin2, V V Kalinichenko2.   

Abstract

Lung cancer is the leading cause of deaths in cancer patients in the United States. Identification of new molecular targets is clearly needed to improve therapeutic outcomes of this devastating human disease. Activating mutations in K-Ras oncogene and increased expression of FOXM1 protein are associated with poor prognosis in patients with non-small-cell lung cancer. Transgenic expression of activated Kras(G12D) in mouse respiratory epithelium is sufficient to induce lung adenocarcinomas; however, transcriptional mechanisms regulated by K-Ras during the initiation of lung cancer remain poorly understood. Foxm1 transcription factor, a downstream target of K-Ras, stimulates cellular proliferation during embryogenesis, organ repair and tumor growth, but its role in tumor initiation is unknown. In the present study, we used transgenic mice expressing Kras(G12D) under control of Sftpc promoter to demonstrate that Foxm1 was induced in type II epithelial cells before the formation of lung tumors. Conditional deletion of Foxm1 from Kras(G12D)-expressing respiratory epithelium prevented the initiation of lung tumors in vivo. The loss of Foxm1 inhibited expression of K-Ras target genes critical for the nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) pathways, including Ikbkb, Nfkb1, Nfkb2, Rela, Jnk1, N-Myc, Pttg1 and Cdkn2a. Transgenic overexpression of activated FOXM1 mutant was sufficient to induce expression of these genes in alveolar type II cells. FOXM1 directly bound to promoter regions of Ikbkb, Nfkb2, N-Myc, Pttg1 and Cdkn2a, indicating that these genes are direct FOXM1 targets. FOXM1 is required for K-Ras-mediated lung tumorigenesis by activating genes critical for the NF-κB and JNK pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213573     DOI: 10.1038/onc.2013.475

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  The NF-κB genomic landscape in lymphoblastoid B cells.

Authors:  Bo Zhao; Luis A Barrera; Ina Ersing; Bradford Willox; Stefanie C S Schmidt; Hannah Greenfeld; Hufeng Zhou; Sarah B Mollo; Tommy T Shi; Kaoru Takasaki; Sizun Jiang; Ellen Cahir-McFarland; Manolis Kellis; Martha L Bulyk; Elliott Kieff; Benjamin E Gewurz
Journal:  Cell Rep       Date:  2014-08-21       Impact factor: 9.423

3.  Is there potential to target FOXM1 for 'undruggable' lung cancers?

Authors:  Vladimir V Kalinichenko; Tanya V Kalin
Journal:  Expert Opin Ther Targets       Date:  2015-05-04       Impact factor: 6.902

4.  LncRNA OSER1-AS1 interacts with miR-612/FOXM1 axis to modulate gefitinib resistance of lung adenocarcinoma.

Authors:  Tingting Shi; Weijuan Sun; Yan-Long Shi; Qiang Wang; Ze-Xuan Yan; Mei Zhang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 5.  Building and Regenerating the Lung Cell by Cell.

Authors:  Jeffrey A Whitsett; Tanya V Kalin; Yan Xu; Vladimir V Kalinichenko
Journal:  Physiol Rev       Date:  2019-01-01       Impact factor: 37.312

6.  Forkhead box F2 regulation of platelet-derived growth factor and myocardin/serum response factor signaling is essential for intestinal development.

Authors:  Craig Bolte; Xiaomeng Ren; Tatiana Tomley; Vladimir Ustiyan; Arun Pradhan; April Hoggatt; Tanya V Kalin; B Paul Herring; Vladimir V Kalinichenko
Journal:  J Biol Chem       Date:  2015-01-28       Impact factor: 5.157

7.  Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.

Authors:  Dragana Kopanja; Akshay Pandey; Megan Kiefer; Zebin Wang; Neha Chandan; Janai R Carr; Roberta Franks; Dae-Yeul Yu; Grace Guzman; Ajay Maker; Pradip Raychaudhuri
Journal:  J Hepatol       Date:  2015-03-28       Impact factor: 25.083

8.  The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin.

Authors:  Samriddhi Shukla; David Milewski; Arun Pradhan; Nihar Rama; Kathryn Rice; Tien Le; Matthew J Flick; Sara Vaz; Xueheng Zhao; Kenneth D Setchell; Elsa Logarinho; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  Mol Cancer Ther       Date:  2019-04-30       Impact factor: 6.261

Review 9.  RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Authors:  Bingliang Fang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-09-07       Impact factor: 3.848

Review 10.  Fox transcription factors: from development to disease.

Authors:  Maria L Golson; Klaus H Kaestner
Journal:  Development       Date:  2016-12-15       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.